NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinar... ( ...)

HOME >> MEDICINE >> TECHNOLOGY

NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress

Date:9/22/2009

BERLIN and SAN CARLOS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented favorable data today on lead oncology program, NKTR-102, demonstrating encouraging Phase 1 and preclinical anti-tumor activity of the investigational compound in ovarian cancer. These data were presented at the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany.

"As highlighted in our data presented today at ECCO/ESMO, we continue to see encouraging signs suggesting that NKTR-102's improved pharmacokinetics could result in an enhanced therapeutic profile," said Lorianne Masuoka, M.D., Chief Medical Officer. "We are also pleased with the rapid enrollment of the first stage of our Phase 2 clinical study in platinum-resistant ovarian cancer. Although many patients are not yet evaluable for response, we have already achieved a sufficient number of confirmed responses to open the second stage for both regimens in the study earlier than anticipated. This important new compound may offer a valuable new treatment option to overcome chemo-resistance in patients with recurrent ovarian cancer."

NKTR-102 is a novel prodrug of irinotecan that was designed using Nektar's proprietary small molecule advanced polymer conjugate technology platform. Nektar's proprietary technology is being used to significantly improve the half-life and potentially enhance the therapeutic profile of important chemotherapeutic agents and also to create novel, oral small molecule drug candidates across multiple therapeutic areas.

In the preclinical studies presented today, NKTR-102 was evaluated at three dose levels and compared to three equivalent dose levels of irinot
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
6. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
7. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
8. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
9. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
10. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
11. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes

Post Your Comments:

(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...

(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...

(Date:5/16/2013)... , May 16, 2013 Nektar Therapeutics, (Nasdaq: ... W. Robin , is scheduled to present at the ... York at the Sheraton New York Hotel on ... The presentation will be accessible via a Webcast through ... of the Nektar website: http://www.nektar.com . This Webcast will ...

Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2 Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2

[0] Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.[0] A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing [0] Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

... 2012 Enanta Pharmaceuticals, Inc. , a research ... molecule drugs in the infectious disease field, announced ... collaboration and license agreement with Novartis for the ... development candidate, EDP-239, from its NS5A hepatitis C ...

... 21, 2012 Fourth-Quarter 2011 Highlights: ... $1.08 increased 22.7 percent; Diluted EPS of $1.14, excluding ... with Express Scripts, Inc., increased 29.5 percent over $0.88 ... all intangible amortization and merger-related expenses, increased 26.3 percent ...

Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings

(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...

(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...

(Date:5/18/2013)... Adolescents, especially young males, who experiment with synthetic ... landing in emergency rooms across America. Recovery ... with a new treatment program for those addicted to ... the National Institute on Drug Abuse, synthetic marijuana has ... In 2012, 11 percent of high school seniors had ...

(Date:5/18/2013)... May 18, 2013 The American ... John A. Kitzhaber, M.D., (D) to sign a bill ... prohibiting minors under the age of 18 from tanning ... the third state in the nation to enact an ... similar indoor tanning bans for minors. Nationwide, 34 states ...

(Date:5/18/2013)... The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). One can earn ... These trainings are suitable for business analysts, project managers, developers, ... will be a part of the Scrum team, people outside ... and Scrum, but are unsure of what it is. ...

Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3 Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2 Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3 Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2 Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2 Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2 Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3

[0] Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets [0] Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights [0] Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates [0] ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions [0] Affordable Scrum Trainings In Irvine by Conscires Agile Practices

... Justin Timberlake; Sam, Younes and David Nazarian; and Sandy and ... at their annual Gala on Wednesday, November 4, 2009 at ... The event, sponsored by Lexus, benefitted the Cedar-Sinai Board of ... for the cause. , Justin Timberlake was ...

... YORK, Nov. 5 Wolters Kluwer Health has announced the ... the new position of Chief Nursing Officer (CNO) in a ... & Wilkins (LWW) journals and Ovid brands. LWW is a ... the global leader in electronic medical, scientific, and academic information ...

... Corporation (NYSE: KMB ) today announced the expiration ... Act with respect to its previously announced planned acquisition ... cash tender offer on October 20, 2009 to purchase ... tender offer will expire at midnight on November 17, ...

... Nov. 5 Narconon International,s management office in Los ... throughout the country in a combined effort to speak ... Red Ribbon Week. , The National Family Partnership,s (NFP) ... drug prevention activities and is held during the end ...

... Executive Vice President of the University of Pennsylvania for ... receive the Abraham Flexner Award for Distinguished Service to ... (AAMC). The award will be presented on Saturday, Nov. ... The Flexner Award was established by the ...

... ... increase awareness about the disease, raise funds for The Association’s global research program through an ... patients.” , ... (Vocus) November 5, 2009 -- As every caregiver who helps take care of someone living ...

Cached Medicine News:Health News:2009 Cedars-Sinai Board of Governors Gala Sponsored by Lexus Raises Over $2.6 Million 2 Health News:Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market 2 Health News:Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market 3 Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 2 Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 3 Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 4 Health News:Narconon Centers Educate Thousands During Red Ribbon Week 2 Health News:Penn's Arthur H. Rubenstein receives Distinguished Service award from AAMC 2 Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 2 Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 3 Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 4 Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 5

2009 Cedars-Sinai Board of Governors Gala Sponsored by Lexus Raises Over $2.6 Million Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation Narconon Centers Educate Thousands During Red Ribbon Week Penn's Arthur H. Rubenstein receives Distinguished Service award from AAMC Caregiver's National Quilt Contest Supports ALS Association's Global Research Program

... color perception charts are recognized internationally ... determining color deficiency. With normal color ... all be visible. Each color test ... is specially printed to measure incrementally ...

Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...

... BD Edgeahead Stiletto / MVR knife. 1.1 ... insertion of 1.1 mm (19G) Cannula (5/bx, 1 ... knives are consistently sharp and precise. Sure grip ... edge. Tapered tip creates a fluid tight incision ...

Medicine Products:

Ishihara Color Test Ishihara Test Unlettered Pediatric 10 Plate Book Ishihara Test 14 Plate Book BD Edgeahead